Quick Answer
Rani Therapeutics Holdings, Inc. reported Stockholders Equity of $33.01 million for the year ending 2025.
- Rani Therapeutics Holdings, Inc. showed an increase of +1,557.1% in Stockholders Equity from 2024 to 2025.
- This data is from Rani Therapeutics Holdings, Inc.'s annual report (Form 10-K), filed with the SEC on March 26, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2021: $51.37 million | Q1 2022: $53.38 million | Q2 2022: $47.81 million | Q3 2022: $42.19 million | Q1 2023: $30.72 million | Q2 2023: $24.09 million | Q3 2023: $17.55 million | Q1 2024: $7.40 million | Q2 2024: $2.84 million | Q3 2024: $3.12 million | Q1 2025: -$3.06 million | Q2 2025: -$5.58 million | Q3 2025: -$7.86 million.
- Over the full 6 years of available data (2020 to 2025), Rani Therapeutics Holdings, Inc.'s Stockholders Equity has grown by 129.1%.
- Historical annual values: Fiscal year 2025: $33.01 million | Fiscal year 2024: $1.99 million | Fiscal year 2023: $12.87 million | Fiscal year 2022: $36.86 million | Fiscal year 2021: $47.41 million | Fiscal year 2020: -$113.34 million.
- Data sourced from SEC EDGAR public filings as of August 4, 2026.
Last verified: